324 Blackwell Street
Bay 12, Suite #1220
About Dermavant Sciences
Dermavant Sciences is dedicated to developing and, upon regulatory approval, commercializing innovative therapies in medical dermatology. Dermavant has four clinical-stage drugs in development: RVT-501, RVT-502, RVT-503, and RVT-201.
RVT-501 is a highly potent and selective topical phosphodiesterase-4 inhibitor currently in development for patients with mild-to-moderate atopic dermatitis. RVT-502, also known as cerdulatinib, is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor being developed as a topical therapy for a variety of serious dermatologic conditions. RVT-503 is an undisclosed preclinical asset being studied for the treatment of acne. RVT-201 is a caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines and is being developed for inflammatory skin diseases.
Founder: Vivek Ramaswamy
Executive Chair: Jackie Fouse, PhD
CMO: Jim Lee, MD, PhD
Please click here for Dermavant Sciences' pipeline.
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.